13 April 2018 - - New York, New York-based biopharmaceutical and healthcare products specialist Pfizer Inc. (NYSE: PFE) has joined the Cambridge, Massachusetts-based global health research network TriNetX, the network said.
As a member, Pfizer will have access to clinical data from TriNetX's network of healthcare organizations to support clinical study and protocol design, site identification, and patient recruitment for clinical trials across a range of therapeutic areas and development stages.
TriNetX connects healthcare organizations, biopharmaceutical companies, and contract research organizations to collaborate, enhance trial design, accelerate patient recruitment, conduct in-depth research, and help bring new therapies to market faster.
Through TriNetX's cloud-based platform, researchers are able to analyze patient populations and perform "what-if" analyses in real-time.
Users of the platform are presented with aggregate views, but each data point in the network can be traced to healthcare organizations who have the ability to identify patients, allowing clinical researchers to develop virtual patient cohorts for potential recruitment into a clinical trial.
The TriNetX network will help Pfizer to recruit hard-to-find patients with rare diseases and to identify sites with access to patients who meet inclusion and exclusion criteria.
Pfizer discovers, develops, manufactures, and sells healthcare products worldwide. Its global portfolio includes medicines and vaccines as well as consumer health care products. The company collaborates with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world.
Each member of the TriNetX community shares in the consolidated value of its global, federated health research network that connects clinical researchers in real-time to the patient populations which they are attempting to study.